Valuation: Theracryf Plc

Market Cap 6.17M 5.4M 4.95M 4.62M 8.76M 588M 8.91M 59.65M 23.12M 288M 23.18M 22.68M 993M P/E 2026 *
-1.44x
P/E 2027 * -1.76x
Enterprise Value 4.02M 3.52M 3.23M 3.01M 5.71M 383M 5.8M 38.87M 15.06M 188M 15.11M 14.78M 647M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day+0.93%
1 week+0.93%
Current month+0.93%
1 month-9.58%
3 months+11.28%
6 months+8.50%
Current year+8.50%
1 week 0.21
Extreme 0.21
0.22
1 month 0.21
Extreme 0.21
0.26
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25Others

Director

422,727,272 19.8499%
04/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+0.93%-14.90%-92.89% 6.17M
-1.04%+4.16%+77.45%+133.83% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.52%+9.17%+43.81%-28.35% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.19%+7.11%+46.84%+119.26% 24.21B
Weighted average by Cap. +0.98%+7.21%+57.53%+136.10%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.93M -2.69M -2.51M -4.75M -319M -4.83M -32.37M -12.55M -156M -12.58M -12.31M -539M -3.43M -3M -2.75M -2.57M -4.86M -326M -4.95M -33.13M -12.84M -160M -12.88M -12.6M -552M
Net Debt -2.15M -1.88M -1.73M -1.61M -3.05M -205M -3.1M -20.78M -8.05M -100M -8.08M -7.9M -346M 453K 396K 364K 339K 643K 43.17M 654K 4.38M 1.7M 21.17M 1.7M 1.67M 72.96M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
03/07/26 GBX 0.2170 +0.93% 3,487,495
02/07/26 GBX 0.2150 0.00% 125,772
01/07/26 GBX 0.2150 0.00% 3,949,679
30/06/26 GBX 0.2150 0.00% 960,735
29/06/26 GBX 0.2150 0.00% 1,911,416
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002873USD
Average target price
0.0431USD
Spread / Average Target
+1,401.43%

Annual profits - Rate of surprise